Assembly Biosciences

Assembly Biosciences Debt

The Debt of Assembly Biosciences (ASMB) as of Nov 5, 2026 is 569,000.00 USD.

Debt

569,000.00USD

Last updated:

In 2025, Assembly Biosciences's total debt was 569,000.00 USD, a % change from the 0.00 USD total debt recorded in the previous year.

The Assembly Biosciences Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
569,000.00 USD
The Assembly Biosciences Debt history
YEARDebtYoY
569,000.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Assembly Biosciences Stock analysis

What does Assembly Biosciences do? Assembly Biosciences develops oral therapeutics for hepatitis B virus (HBV) infection through its CpAM platform, targeting the HBV core protein with small molecules. The company also focuses on microbiome restoration using GEMICEL, an oral delivery system for live biologic therapies targeting the lower gastrointestinal tract. Its lead product candidate is in development for chronic hepatitis B virus and dysbiotic microbiome conditions. The company's primary products include CpAMs for HBV treatment and GEMICEL-based microbiome therapeutics, designed for patients with chronic HBV and microbiome-related illnesses. These products are developed for medical use in infectious disease management, targeting healthcare providers and pharmaceutical partners seeking novel therapeutic solutions. Assembly Biosciences' revenue streams are derived from the development and potential future commercialization of its HBV and microbiome platform programs, with no current indication of licensing or partnership agreements mentioned in the business description. Assembly Biosciences is one of the most popular companies on Eulerpool.

Debt Details

Understanding Assembly Biosciences's Debt Structure

Assembly Biosciences's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Assembly Biosciences's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Assembly Biosciences’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Assembly Biosciences’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Assembly Biosciences stock

Debt of Assembly Biosciences is 569,000.00 USD in 2025.

On Eulerpool you can find the complete historical development of Debt Assembly Biosciences since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Assembly Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Assembly Biosciences

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Assembly Biosciences